SCYX today
$3.15-$0.18 (-5.41%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minExpanding
Daily trend turns up above $4.04
Key levels
Resistance$3.66
Resistance$3.28
Latest news & SEC filings
EarningsSCYNEXIS Posts Q3 2026 Results, Issues Business Update
DealScynexis files $200M mixed shelf offering
SEC FilingScynexis Inc filed a shelf registration for future offerings (Form S-3)
EarningsSCYNEXIS posts quarterly loss of $0.71 per share, topping $0.72 estimate
All SCYX news →About Scynexis
Scynexis is a biopharmaceutical company developing antifungal medicines. Its lead product, ibrexafungerp (BREXAFEMME), is approved in the U.S. for vulvovaginal candidiasis and is licensed to GSK for commercialization. The company is also developing SCY-247, an oral and intravenous antifungal candidate for invasive fungal infections, and has collaboration agreements covering China and Russia. It operates in the United States and relies on third-party manufacturers.
Based on the company's 10-K filed Mar 4, 2026.
Nasdaq · Healthcare
SCYNEXIS INC (SCYX)
What Is the Price Target for SCYX?
SEPT Low Target
$33.00
SEPT Mid Target
$33.00
SEPT High Target
$33.00
Analyst Consensus
$33.00
Is SCYX a Buy or Sell Right Now?
Thesis
- •Revenue growing 449.9% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SCYX.
Start Free Trial →Is SCYX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
PEG, Analyst Consensus
Fair Value
$20.32
27
Moat Score
NONE
5/9
Piotroski Score
3.3
Altman Z-Score
What Is Smart Money Doing with SCYX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Burke Steven Keith | director | Buy | 5,750 | - | Sep 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SCYX Growth Story
Revenue YoY
449.9%
3yr Revenue CAGR
59.4%
EPS Growth YoY
61.36%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for SCYX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SCYX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:33:07 | $3.20 | 5,000 | $$16K | BUY |
| 15:34:40 | $3.22 | 1,000 | $$3K | BUY |
| 15:16:42 | $3.23 | 1,000 | $$3K | BUY |
| 14:45:03 | $3.35 | 1,000 | $$3K | SELL |
| 20:31:18 | $3.33 | 5,000 | $$17K | MIDPOINT |
5 dark pool trades shown · $$42K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for SCYNEXIS INC (SCYX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SCYX — frequently asked questions
What is SCYX stock price today?
SCYNEXIS INC (SCYX) is at $3.15, down 5.41% (-$0.18) at the Nov 13, 2026 close.
Why is SCYX stock moving today?
Latest SCYX news — Nov 5, 2026: SCYNEXIS Posts Q3 2026 Results, Issues Business Update · Nov 5, 2026: Scynexis files $200M mixed shelf offering
What is the SCYX price target?
The average analyst price target for SCYX is $33.00, ranging from $33 to $33, based on 1 analysts. Latest: Guggenheim maintains on Aug 13, 2026.
What do analysts rate SCYX?
Analyst ratings for SCYX: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did SCYX beat earnings?
SCYX last reported on Aug 12, 2026: EPS $0.63 vs -$0.51 expected — a beat of 224.3%.
What is SCYX's P/E ratio?
SCYX trades at a P/E of 3.0 vs a Healthcare average of 18.5.
Does SCYX pay a dividend?
SCYX does not currently pay a dividend.
What are SCYX support and resistance levels?
Resistance: $3.28, $3.66, $4.00.
What are insiders doing with SCYX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on SCYX?
Nov 5, 2026: SCYNEXIS Posts Q3 2026 Results, Issues Business Update · Nov 5, 2026: Scynexis files $200M mixed shelf offering · Nov 5, 2026: Scynexis Inc filed a shelf registration for future offerings (Form S-3)